The U.S. Congress, Select Committee on the Chinese Communist Party (CCP), has announced a hearing scheduled for tomorrow, Tuesday, April 16th, at 8:00 a.m., focusing on “The CCP’s Role in the Fentanyl Crisis.”
This issue has been on my radar since 2019, and I’ve penned several posts about it. (See attached links below.)
Back in November 2019, the death toll in the U.S. due to fentanyl overdose stood at 30,000. Fast forward to 2022, as per the 2023 DOJ announcement, and that number has surged to a staggering 110,000 Americans.
Last year, the U.S. Department of Justice made headlines with indictments against various Chinese-based fentanyl chemical manufacturing companies implicated in the production of these lethal fentanyl precursors.
ADDITIONAL REPORTING
New York Times — June 23, 2023 – U.S. Charges Four Firms with Selling Chemicals to Make Fentanyl
60 Minutes REWIND — April 28, 2019 – Buying Fentanyl Online from China
HBO — 2018 – How Fentanyl Gets to the U.S. from China
CRUCIAL QUESTIONS
In my previous writings, I’ve posed some crucial questions:
- Does the inundation of deadly fentanyl into the United States align with the Communist China ‘Influence and Interference’ playbook?
- Is China’s Ministry of State Security (MSS) supervising China-based chemical companies involved in this fentanyl flooding campaign?
If your schedule permits, I strongly encourage you to tune in to this hearing or catch the recording afterward. It’s a critical issue that demands attention and understanding.
Additional Reading:
IP Probe Blog – October 12, 2023 – The Ongoing Fentanyl Menace: China’s Precursors and a Deadly Additive
NY Times – October 5, 2023 – Some Key Facts About Fentanyl
IP Probe Blog – July 7, 2023 – Chinese Fentanyl and the U.S. Overdose Epidemic-UPDATE
IP Probe Blog – November 14, 2019 – Chinese Fentanyl and the U.S. Overdose Epidemic
Disclaimer: IPProbe.Global is a service to the professional IP community. While every effort has been made to check the information in this blog, we provide no guarantees or warranties, express or implied, regarding the content provided in IPProbe.Global. We disclaim all liability and responsibility for the qualification or accuracy of representations made by the contributors or for any disputes that may arise. It is the responsibility of the readers to independently investigate and verify the credentials of such persons and the accuracy and validity of the information provided by them. This blog is for general information only and is not intended to provide legal or other professional advice.